University of South Florida pulmonologist Dr. Jose Herazo-Maya has focused his career on researching treatments for pulmonary fibrosis, a devastating and deadly lung disease. Pulmonary fibrosis in ...
A new inhaled therapy targeting lung inflammation shows promise in reducing damage and improving recovery after severe ...
The study of long COVID remains in its infancy, with no FDA-approved treatment available, but the pandemic may be spawning new research into other medical areas, says the head of Northwestern's long ...
NTU Singapore is working with China's Southern University of Science and Technology (SUSTech) and Swedish biotechnology ...
MINNEAPOLIS--(BUSINESS WIRE)--Humanetics Corporation (Humanetics) announced today the results of its Phase 2 clinical trial of BIO 300 Oral Suspension (BIO 300) for the mitigation of impaired ...
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the pathogen responsible for the coronavirus disease 2019 (COVID-19), has been associated with the manifestation of adverse pulmonary ...
A new inhaled therapy targets ANGPTL4 to reduce lung inflammation, fluid buildup, and scarring after infections. Preclinical ...
Petrovax announced today the positive results from “Long-CoV-III-21,” a randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of bovhyaluronidase azoximer in adult ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results